Kroger will begin phasing out their printed ads in certain markets, including those in Michigan, Indiana, Mississippi and Oregon, this May. Customers will only be able to access print ads by going ...

Arexvy is a brand-name respiratory syncytial virus (RSV) vaccine. It’s used in some adults to help prevent lung disease from RSV. Arexvy should not be used during pregnancy and breastfeeding ...

Pharmaceutical giant GSK has won a key part of the regulatory approval needed to roll out its vaccine for respiratory syncytial virus (RSV) to adults aged 50 to 59. The US Food and Drug ...

Are you a print subscriber? Activate your account. By Ad Age Staff - 12 min 52 sec ago By Ad Age and Creativity Staff - 1 hour 21 min ago By Brandon Doerrer - 2 hours 27 min ago By Brian Bonilla ...

AREXVY is approved for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older, as well as individuals 50 ...

Findings showed a noninferior immune response for both vaccines when coadministered compared with separate administration. Topline results were announced from a phase 3 study assessing the immune ...

AD&D insurance usually comes with significant coverage limitations, so always read the fine print. AD&D does not pay if the insured died due to natural causes, such as cancer or heart disease.

Several Big Pharmas took home trophies at the annual Fierce Pharma Marketing Awards on Wednesday night. | Several Big Pharmas took home trophies at the annual Fierce Pharma Marketing Awards on ...

GSK plc (LSE/NYSE: GSK) today announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, reactogenicity and safety of AREXVY (Respiratory ...